Pharmaceutical compliance support in Sweden
Local rules, connected to your global model.
Eunomia helps pharmaceutical and biotech teams scope compliance support for Sweden, connecting medicines-information review, healthcare collaboration and transparency processes with global governance. We agree the expertise and delivery arrangements required for your activities.
Discuss this service
Who this support is for
For pharmaceutical companies planning Swedish activities, regional teams extending a Nordic operating model and biotech organisations building their first commercial compliance processes. The starting point is a defined activity scope, rather than assuming one Nordic approach fits every country.
The practical challenge in Sweden
A global policy may not explain how Swedish healthcare collaboration, local medicines information and disclosure processes work in practice. Teams need clear ownership across headquarters, affiliates and third parties, including responsibility for local-language material and changes after initial approval.
How Eunomia can help
We can help structure a market-readiness review, identify gaps between global processes and Swedish activities, and build an action plan with accountable owners. Scope can include engagement workflows, material-review coordination, payment-data controls and monitoring. Swedish-language review, specialist advice and any designated role are confirmed before engagement, rather than assumed.
Your first working priorities
- Identify which Swedish rules and contractual code commitments apply to each activity and third party.
- Map local-language assets and digital channels to a review owner, version history and escalation process.
- Connect healthcare collaboration requests to documented purpose, agreements, compensation review and retained evidence.
- Prepare disclosure data and a methodology note early, with responsibility for Swedish publication requirements and reconciliation.
Programme design and implementation · Operational shared services · Compliance automation
What we can take on
Pharmaceutical compliance in Sweden: scope of support
HCP and patient organisation engagement review
Local transparency and disclosure requirements
Promotional and non-promotional material review
Market-entry compliance assessment
Specialist and language requirements assessment
What this gives you
Sweden requirements built into your global processes
Clear responsibilities for review and escalation
Local support without unnecessary fixed headcount
The rules in Sweden
What shapes compliance in Sweden…
A short guide to the main legal and self-regulatory frameworks. Each summary links to its official source below.
Medicines advertising and the national regulator
The Swedish Medical Products Agency supervises medicines advertising. Its published overview states that advertising must not mislead or encourage misuse, and that only authorised or registered medicines may be advertised. Check the relevant product and audience before adapting a campaign for Sweden.
Lif ethical rules: LER
LER complements legislation and covers human medicines. Its scope identifies Lif, ASCRO and FGL member companies and includes responsibilities for activities conducted through intermediaries. It addresses medicines information and healthcare collaboration. Check the applicable version and commitments before translating these requirements into an operating procedure.
Healthcare collaboration and transparency
Lif’s published rules cover healthcare collaboration and disclosure of transfers of value. The disclosure section includes annual reporting, a methodology note and Swedish-language publication. It also specifies searchable, downloadable reports from the 2027 publication of 2026 transfers. Plan the data and publication workflow together.
Review and escalation
LER describes the roles of IGN and NBL in industry self-regulation. For operational readiness, define who reviews local materials, assesses questions and coordinates a response if an issue arises. Keep the final approved version, supporting evidence and subsequent changes accessible to that team.
Primary references
This overview is informational and does not constitute legal advice. Scope and application should be confirmed for the organisation, market, activity and counterparty in question. Sources checked September 2026.
Questions, answered
Pharmaceutical compliance in Sweden FAQs
Is a global EFPIA process enough for Sweden?
It is a starting point. Assess the Swedish legal requirements and applicable LER provisions, then identify local changes to your global process. Record ownership for local review, healthcare collaboration and disclosure.
Who is covered by LER?
The English LER edition effective 1 February 2026 identifies Lif, ASCRO and FGL member companies in its scope. It also addresses group-company activities and intermediaries. Confirm membership, contractual commitments and activity scope for your own organisation.
What should we prepare for Swedish disclosure?
Confirm reportable interactions, recipient information and reconciliation responsibilities. Lif’s disclosure rules address a methodology note and publication in Swedish; they also specify searchable and downloadable reports from the 2027 publication of 2026 transfers. Check the current rules when preparing the report.
Can Eunomia provide a Swedish office or named local representative?
This page does not claim a Swedish office or a named local representative. We agree support scope and confirm specialist expertise, language needs and any formal role before an engagement begins.
Tell us what is on your desk.
We will listen, ask a few questions and recommend the right scope—without obligation or pressure.
Start a conversation